

Relative Coronavirus Disease 2019 Mortality: A Swiss Population-based Study

Torsten Hothorn (0000-0001-8301-0471), Matthias Bopp, Huldrych F. Günthard, Olivia Keiser, Maroussia Roelens, Caroline E. Weibull, Michael J. Crowther

Torsten Hothorn, professor

Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich, 8001 Zürich, Switzerland, <torsten.hothorn@uzh.ch>

Matthias Bopp, group leader

Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich, 8001 Zürich, Switzerland, <matthias.bopp@uzh.ch>

Huldrych F. Günthard, professor

Klinik für Infektionskrankheiten und Spitalhygiene, Universitätsspital Zürich, 8091 Zürich, Switzerland and Institut für Medizinische Virologie, Universität Zürich, 8057 Zürich, Switzerland, <huldrych.guenthard@usz.ch>

Olivia Keiser, professor

Institut de santé globale, Université de Genève, 1202 Genève, Switzerland, <Olivia.Keiser@unige.ch>

Maroussia Roelens, postdoctoral researcher

Institut de santé globale, Université de Genève, 1202 Genève, Switzerland, <maroussia.roelens@unige.ch>

Caroline E. Weibull, biostatistician

Department of Medicine Solna, Karolinska Institutet, 171 77 Stockholm, Sweden, <caroline.weibull@ki.se>

Michael J. Crowther, associate professor

Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK and Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden, <mjc76@leicester.ac.uk>

Correspondence to:

Torsten Hothorn, Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich
Hirschengraben 84, CH-8001 Zürich, Switzerland

<Torsten.Hothorn@uzh.ch>

+4144 44 634 48 17

Abstract

Objective Severity of the coronavirus disease 2019 (covid-19) has been assessed in terms of absolute mortality in SARS-CoV-2 positive cohorts. An assessment of mortality relative to mortality in the general population is presented.

Design Retrospective population-based study.

Setting Individual information on symptomatic confirmed SARS-CoV-2 patients and subsequent deaths from any cause were compared to the all-cause mortality in the Swiss population of 2018. Starting February 23, 2020, mortality in covid-19 patients was monitored for 80 days and compared to the population mortality observed in the same time-of-year starting February 23, 2018.

Participants 5 160 595 inhabitants of Switzerland aged 35 to 95 without covid-19 (general population in spring 2018) and 20 769 persons tested positively for covid-19 (spring 2020).

Measurements Sex- and age-specific mortality rates were estimated using Cox proportional hazards models. Absolute probabilities of death were predicted and risk was assessed in terms of relative mortality by taking the ratio between the sex- and age-specific absolute mortality in covid-19 patients and the corresponding mortality in the 2018 general population.

Results A confirmed SARS-CoV-2 infection substantially increased the probability of death across all patient groups, ranging from nine (6 to 15) times the population mortality in 35-year old infected females to a 53-fold increase (46 to 59) for 95 year old infected males. The highest relative risks were observed among males and older patients. The magnitude of these effects was smaller compared to increases observed in absolute mortality risk. Male covid-19 patients exceeded the population hazard for males (hazard ratio 1.20, 1.00 to 1.44). Each additional year of age increased the population hazard in covid-19 patients (hazard ratio 1.04, 1.03 to 1.05).

Limitations Information about the distribution of relevant comorbidities was not available on population level and the associated risk was not quantified.

Conclusions Health care professionals, decision makers, and societies are provided with an additional population-adjusted assessment of covid-19 mortality risk. In combination with absolute measures of risk, the relative risks presented here help to develop a more comprehensive understanding of the actual impact of covid-19.

Introduction

Early reports from China and Italy¹⁻⁷ on disease severity of covid-19 caused unprecedented public health interventions around the world, ranging from social distancing measures or school and university closings to complete lockdowns of societies. The absolute mortality in patients diagnosed with covid-19, i.e., the case-fatality rate, has been the main entity used for communicating risks associated with the disease²⁻⁶. Risk factors for mortality risk, most prominently higher age, being male, and preexisting medical conditions, have become publically known^{1,3,4}.

On the current occasion of liberalisation of the most stringent public health interventions in many countries, an assessment of the actual impact of the covid-19 pandemic is called-for. Health care professionals, politicians, and societies at large currently engage in a discussion about the appropriateness of the mitigation measures taken, and the first scientific contribution on the matter has arisen⁸.

The probability of death estimated from hundreds of thousands of covid-19 patients are constantly reported from many countries^{2-4,9}. These numbers can, however, be hard to compare, due to differences in testing regimes, varying ascertainment of mortality, different age structures of societies, or different health-care and public health systems¹⁰. As an alternative risk difference of disease impact, excess numbers of deaths has been reported for some populations, i.e., the number of observed all-cause deaths during the time of the covid-19 pandemic (end of February to mid-May 2020 in most European countries) minus the expected number of deaths in the given population. Reports on the number of excess deaths observed since the onset of the pandemic are available from Portugal¹¹, Spain¹², northern Italy^{13,14}, various other European countries¹⁵, and the United States¹⁶. However, cross-country comparisons are again difficult, because the success or failure of public health interventions and possible overruns of hospital capacities will be reflected in the presence and magnitude of excess mortality¹⁴.

The emergence of mature data on the course of the covid-19 pandemic from many countries allows its actual impact on societies and health-care systems to be discussed in light of the short-term relative mortality. This relative risk compares the absolute all-cause mortality observed in patients diagnosed with covid-19 during the spring 2020 outbreak with the absolute all-cause mortality in the uninfected population of earlier years during the same calendar time of year. The population mortality varies between females and males, and over attained age, with males and older individuals experiencing a higher short-term risk of dying. How much of the increased mortality reported for male and older covid-19 patients^{1,4,6,7} can be attributed to the increase in population mortality risk in general is an important question awaiting an answer. Furthermore, sex- and age-specific relative covid-19 mortality allows a stratified assessment of risk-increase caused by a SARS-CoV-2 infection¹⁷.

We report age-adjusted relative covid-19 mortalities for females and males based on an analysis of individual population level and covid-19 death records from Switzerland covering the time

between 2020-02-24 and 2020-05-14.

Methods

Study design and data sources

For this population-based study, Swiss general population data from 2014–2018, including individual death records, were obtained from the Swiss Federal Statistical Office (Bundesamt für Statistik). In addition, covid-19 surveillance reports from the Swiss Federal Office of Public Health (Bundesamt für Gesundheit) on an unselected group of individuals tested positively for SARS-CoV-2 between 2020-02-24 and 2020-05-14 were available, also including individual dates of tests and occurred deaths.

Official SARS-CoV-2 testing in Switzerland was performed by polymerase chain reaction (PCR) only, based on lower and upper respiratory tract samples from symptomatic persons. Individuals experiencing the following symptoms were eligible for testing¹⁸: cough, sore throat, muscle pain, dyspnea (with or without fever), and acute anosmia or ageusia. Testing of asymptomatic persons was only recommended to control local outbreaks in hospitals or nursing homes. All positive and negative SARS-CoV-2 test results were directly reported to the Federal Office of Public Health, patients were followed-up subsequently.

Study population

The study population consists of two cohorts. The first cohort consists of persons with a SARS-CoV-2 positive PCR test between 35 and 95 years of age at time of testing. Individuals tested post-mortem or after hospitalisation were not included as the aim was to study relative mortality in a cohort of newly infected people who did not have a short-term increased mortality risk. We refer to this cohort as the “Swiss covid-19” cohort in the sequel. The second cohort was defined as all inhabitants of Switzerland alive on February 23, 2018 aged 35 to 95 years.

Table 1 describes the selection process defining the study population. The Swiss 2014 to 2017 study populations were defined analogously.

[Table 1 about here.]

Statistical analysis

Data was analysed using survival analysis. For the Swiss population cohort, follow-up started on February 23, 2018, and ended at date of death or on date of administrative censoring (May 14, 2018). The underlying time scale for all analyses was time since February 23, measured in days.

The Swiss covid-19 cohort was handled in two different ways. Throughout, follow-up started on the day of the positive test and ended at time of death or on date of administrative censoring (May 14, 2020). When estimating relative rates (contrasting to the general population), the underlying time scale was time since February 23 (measured in days), using a delayed entry approach. For predicting the probability of death, number of days since positive test was used as the underlying time scale.

Sex- and age-specific hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using a stratified Cox proportional hazards model, allowing for separate baseline rates in the Swiss covid-19 and Swiss 2018 population cohorts, with 65-year old females as reference. Sex and age were modelled with main effects only for the Swiss 2018 cohort, whereas for the Swiss covid-19 cohort, interaction effects between SARS-CoV-2 status and sex and age were included to capture the additional mortality effects among the patients. *P*-values and 95% confidence intervals for hazard ratios were adjusted for multiplicity.

To quantify the impact on mortality associated with a SARS-CoV-2 diagnosis, the 60-day probability of death was predicted from the fitted model estimates, which captures deaths occurring within 60 days of February 23 or positive test, for the Swiss 2018 population cohort and Swiss covid-19 cohort, respectively. Using these probabilities, the sex-specific relative mortality (and associated 95% confidence bands) was calculated by taking the ratio between the two, along an age gradient between 35 and 95 years. The relative mortality incorporated uncertainty in the Swiss covid-19 cohort only¹⁹.

The assumption of proportional hazards was assessed by fitting models allowing for time-varying effects. Potential deviations from the linear age effect were assessed in a Cox model allowing nonlinear effects of age. The main-effects only model was compared to a model including sex × age interactions. As a sensitivity analysis, all models were re-fitted using the Swiss 2014 to 2017 general populations as reference. Further details on the statistical analyses performed can be found in the Online Supplement.

All analyses were performed in the R system for statistical computing²⁰ (version 4.0.1) with the **survival**²¹ and **mlt**^{22,23} add-on packages and independently replicated in Stata²⁴ (version 16), using the **stpm2**^{25,26} and **merlin**²⁷ commands.

Results

The daily number of deaths observed during the 80-day study period (2020-02-24 to 2020-05-14) in the Swiss covid-19 cohort increased rapidly from mid-March and peaked during the first days of April, in both males and females (Figure 1). The numbers reduced to less than ten reported deaths per day during the last week of the study period.

[Figure 1 about here.]

Characteristics of the Swiss covid-19 cohort, the Swiss 2018 population cohort, and the earlier Swiss population cohorts (2014-2017) are presented in Table 2. The ratio of females to males indicate that patients in the Swiss covid-19 cohort were more likely female. The mean age was similar between the two cohorts, with SARS-CoV-2 positive patients being between one and a half (females) and up to three years (males) older than individuals in the Swiss population cohort. The similarity was further observed when comparing the whole age distribution among females and males, between cohorts (Figure 2). However, there was a slight over-representation of older people, between 85 and 95 years of age, in SARS-CoV-2 positive individuals.

[Table 2 about here.]

[Figure 2 about here.]

The all-cause mortality rate among 65-year old males from the Swiss 2018 population cohort was 1.50 times that among females of the same age. The mortality rate further increased by a factor of 1.09 for each additional year of age (Table 3). In 2018, males experienced the same mortality as females aged 4.74 years older.

The additional increment in the mortality rate for individuals in the Swiss covid-19 cohort were smaller than the sex- and age-effects observed in the Swiss 2018 population cohort (difference in log-HRs between population and patients 0.22, 95% CI 0.02 – 0.41, for the sex effect and 0.04, 95% CI 0.03 – 0.05, for the age effect). Being a male covid-19 patient was associated with a HR of 1.20, relative to males in the general population (Table 3). The hazard ratio comparing the hazard of males to females in the Swiss covid-19 cohort was $1.50 \times 1.20 = 1.80$ (HR, 95% CI: 1.58 – 2.06). Each additional year of age increased the covid-19 mortality rate by a factor of $1.09 \times 1.04 = 1.14$ (HR, 95% CI: 1.13 – 1.14). Formulated alternatively, the age-related hazard doubled every 8.13 life years in the Swiss 2018 population cohort and every 5.42 life years in the Swiss covid-19 cohort. Hazards of male patients were comparable to hazards of female patients 4.60 years older.

[Table 3 about here.]

The 60-day sex- and age-specific probability of death was considerably larger in the covid-19 cohort (Figure 3, top panel). The probability for a 42-year old female diagnosed with covid-19 was about 0.1%, comparable with a 70-year old female in the 2018 population cohort. Similarly, 55-year old infected males were associated with a probability of death around 1%, equivalent to the 95-year old not infected males in the general population. The probability of death in infected individuals was above 10% for females older than 82 and males older than 76 years. The relative mortality in 80-year old covid-19 patients was approximately three times higher than the relative mortality in 40-year old covid-19 patients.

The probabilities of death implied a nearly log-linear function of age, for both females and males, and in both cohorts of the study population. Hence, it follows that the relative risk comparing the mortality in young patients to the mortality in patients aged 20 years older, for example, would be constant regardless of the age of younger group of patients. The slope of the probabilities of death as a function of age was larger in the Swiss covid-19 cohort due to the models' age effect attributable to the infection (Table 3, covid-19 \times Age – 65).

[Figure 3 about here.]

The sex- and age-specific relative mortality (Figure 3 bottom panel and Table 4) ranged from 9.26 (35 year old females) to 53.76 (92 year old males). This is interpreted as a 35 years old infected female was 9.26 times more likely to die within 60 days after the positive test than a 35 years old uninfected female was likely to die within 60 days following February 23, 2018. Fatalities were 53.76 times more likely in 92-year old infected versus non-infected males. However, the 95% confidence bands demonstrated substantial uncertainty in the estimates of this relative risk; the lower confidence band for 35-year old persons was as large as 6.03 for females and 7.99 for males. The relative mortality was largest for 95 year old females and 92 year old males.

[Table 4 about here.]

Sensitivity analyses (see Online Supplement) demonstrated that results reported for the 2018 study population were very close to the results for the 2014 to 2017 study populations. Model diagnostics did not reveal relevant deviations from proportional hazards nor the main effects model, but indications of a nonlinear age effect in the Swiss covid-19 cohort were found. The nonlinear model suggested a continuously and monotonically increasing hazard of age lacking any clear cut-off points for binary risk stratification.

Conclusion

The nine to 53-fold increase in probability of death found in female and male, young and old, symptomatic covid-19 patients from Switzerland in comparison to the Swiss population of 2018 provides novel sex- and age-specific information on the severity of this pandemic. Covid-19 mortality has never previously been reported as a relative risk in direct relation to the mortality in the general population. The comparison of absolute mortalities and case-fatality rates between risk groups of covid-19 patients without any population adjustment are likely to over-estimate the increased mortality in males and older people. As presented here, more than half of the hazard increase observed in male and older patients could be attributed to the generally increased population mortality in these risk groups.

The population-based setting with matched calendar time allows for estimation of covid-19 related mortality in an unselected cohort of symptomatic and diagnosed patients, without the need to differentiate between deaths caused or not caused by covid-19 in terms of death certificate information²⁸. Seasonal effects were implicitly accounted for by comparing cohorts over the same time-of-year. Unlike other population studies estimating excess mortality, the probability of death in these cohorts could not be confounded by ongoing public health interventions or testing coverage²⁸. Using data from Switzerland was especially useful for this type of analysis. The borders to northern Italy and Austria caused covid-19 outbreaks early in the pandemic, broad and uniform symptom-based testing overseen by federal authorities was implemented quickly, and all test results were reported. A symptom-based testing regime was carried out, with testing of asymptomatic persons only recommended to control local outbreaks in hospitals or nursing homes, however, a number of hospitals started to test all patients admitted to the hospital at different time points regardless of symptoms. In contrast to reports from northern Italy¹⁴, the number of covid-19 patients in need for hospitalisation never exceeded health-care capacities, and every patient received the best possible treatment under the circumstances.

Absolute mortalities in the Swiss covid-19 cohort were smaller than those reported for Italian and Chinese covid-19 patients³⁻⁵ between 40 and 80 years old. The numbers are expected to be higher than in Germany, where the overall case fatality rate was only 1.2% and more tests were performed in younger patients with mild symptoms²⁹. Due to differences in testing protocol, substantially higher or lower relative mortality may therefore be expected in other countries. The Swiss covid-19 cohort excluded persons with known increased mortality risks (those tested posthumously or while being hospitalised), as well as very old and thus a priori frail persons. The figures presented here can nevertheless inform models developed for computing prognoses on the number of expected deaths in real or hypothetical populations, because relative mortality is not affected by public health interventions which lead to a reduced or even nonexistent excess mortality in many European countries. For the UK, prognoses assumed a 1-year relative mortality risk not larger than two, uniformly for females and males of all ages³⁰. A short-term 60-day relative mortality larger than nine, as found here, suggests that the actual risk is larger than assumed based on prognostic models. However, the more general question of the true covid-19 relative mortality will be lower than that reported in this study, as the inclusion criteria for the covid-19 cohort was defined on being symptomatic and testing positive for SARS-CoV-2. The true proportion of asymptomatic cases and the actual prevalence are ongoing questions³¹.

The sex- and age effects on all-cause mortality attributable to covid-19 are, however, still relevant and males and older persons were associated with higher risk. Males had a 20% higher mortality rate than females, however, the uncertainty around this hazard ratio was large and the effect was absent in populations of earlier years and in a model with sex \times age interactions (see Online Supplement). The relative mortality (ratio of the probabilities of death) was approximately three times higher among 80-year old than 40-year old covid-19 patients. This population-adjusted comparison of the risk between young and old patients suggest a less drastic relative impact of age on

mortality than previously reported⁸. Stratification into low and high risk groups using a cutoff at 65 years of age, as seen in several published reports and recently advocated for³², seems hard to justify based on the continuously increasing age-specific relative mortalities reported here.

The results suggest that covid-19 risk assessment in terms of case-fatality rates and excess mortalities should be complemented by population-adjusted relative mortalities such that a more complete picture can emerge, potentially leading to improvements for age-based risk stratification.

Contributions TH, MB, and MJC designed the study, preprocessed, and analysed the data. TH prepared an initial draft, all authors reviewed and improved early versions of the manuscript and approved the final version.

Funding Swiss National Science Foundation. The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the final report.

Competing interests TH has been paid for consulting, lectures or presentations from Novartis, Roche, and PricewaterhouseCoopers. HFG has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, Merck and ViiV Healthcare; and grants from SystemsX, and the National Institutes of Health. MJC has been paid for consulting, lectures or presentations from Roche and Reinsurance Group of America UK Services Limited.

Data sharing All results can be reproduced from study cohorts, R and Stata computer code publicly available from https://gitlab.switch.ch/torsthen.hothorn/relative_covid-19_mortality.

References

- [1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *The Lancet* 2020; **395**: 1054–1062. DOI:10.1016/S0140-6736(20)30566-3.
- [2] Odone A, Delmonte D, Scognamiglio T, Signorelli C. COVID-19 deaths in Lombardy, Italy: Data in context. *The Lancet Public Health* 2020; DOI:10.1016/S2468-2667(20)30099-2.
- [3] Onder G, Giovanni, Brusaferro RS. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *Journal of the American Medical Association* 2020; **323**: 1775–1776. DOI:10.1001/jama.2020.4683.
- [4] Task Force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Istituto Superiore di Sanità. Epidemia COVID-19 (version May 15, 2020). Technical report, 2020. URL https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_14-maggio-2020.pdf. Accessed 2020-05-18.
- [5] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. *The Lancet* 2020; DOI:10.1016/S1473-3099(20)30243-7.
- [6] Hauser A, Counotte MJ, Margossian CC, Konstantinoudis G, Low N, Althaus CL, Riou J. Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modelling study in Hubei, China and northern Italy. *medRxiv* 2020; DOI:10.1101/2020.03.04.20031104.
- [7] Ruan S. Likelihood of survival of coronavirus disease 2019. *The Lancet* 2020; DOI:10.1016/S1473-3099(20)30257-7.
- [8] Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. *medRxiv* 2020; DOI:10.1101/2020.04.05.20054361.
- [9] Brown P, Jha P, CGHR COVID Mortality Consortium. Mortality from COVID-19 in 12 countries and 6 states of the United States. *medRxiv* 2020; DOI:10.1101/2020.04.17.20069161.
- [10] Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. *The Lancet Infectious Diseases* 2020; DOI:10.1016/S1473-3099(20)30195-X.
- [11] Nogueira PJ, de Araújo Nobre M, Nicola PJ, Furtado C, Carneiro AV. Excess mortality estimation during the COVID-19 pandemic: Preliminary data from Portugal. *Acta Médica Portuguesa* 2020; DOI:10.20344/amp.13928.
- [12] Trias-Llimós S, Bilal U. Impact of the COVID-19 pandemic on life expectancy in Madrid (Spain). Technical report, 2020. URL <https://osf.io/s53jx/>. Accessed 2020-05-18.
- [13] Ghislandi S, Muttarak R, Sauerberg M, Scotti B. News from the front: Estimation of excess mortality and life expectancy in the major epicenters of the COVID-19 pandemic in Italy. *medRxiv* 2020; DOI:10.1101/2020.04.29.20084335.

- [14] Piccininni M, Rohmann JL, Foresti L, Lurani C, Kurth T. Use of all cause mortality to quantify the consequences of COVID-19 in Nembro, Lombardy: Descriptive study. *British Medical Journal* 2020; **369**: m1835. DOI:10.1136/bmj.m1835.
- [15] Felix-Cardoso J, Vasconcelos H, Rodrigues P, Cruz-Correia R. Excess mortality during COVID-19 in five European countries and a critique of mortality analysis data. *medRxiv* 2020; DOI:10.1101/2020.04.28.20083147.
- [16] Rivera R, Rosenbaum J, Quispe W. Estimating excess deaths in the United States early in the COVID-19 pandemic. *medRxiv* 2020; DOI:10.1101/2020.05.04.20090324.
- [17] Spagnolo PA, Manson JE, Joffe H. Sex and gender differences in health: What the COVID-19 pandemic can teach us. *Annals of Internal Medicine* 2020; DOI:10.7326/M20-1941.
- [18] Bundesamt für Gesundheit (Swiss Federal Office of Public Health). COVID-19: Empfehlungen zur Diagnose (Stand: 24. 4. 2020). Technical report, 2020. URL <https://www.bag.admin.ch/>. Accessed 2020-05-18.
- [19] Ederer F, Axtell LM, Cutler SJ. The relative survival rate: A statistical methodology. *National Cancer Institute Monograph* 1961; **6**: 101–121.
- [20] R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2020. URL <http://www.R-project.org/>.
- [21] Therneau TM. survival: Survival Analysis, 2020. URL <https://CRAN.R-project.org/package=survival>. R package version 3.1-12.
- [22] Hothorn T, Möst L, Bühlmann P. Most likely transformations. *Scandinavian Journal of Statistics* 2018; **45**: 110–134. DOI:10.1111/sjos.12291.
- [23] Hothorn T. mlt: Most Likely Transformations, 2020. URL <https://CRAN.R-project.org/package=mlt>. R package version 1.2-0.
- [24] StataCorp. Stata Statistical Software: Release 16. College Station, TX, U.S.A., 2019.
- [25] Royston P, Parmar MKB. Flexible parametric proportional hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. *Statistics in Medicine* 2002; **21**: 2175–2197. DOI:10.1002/sim.1203.
- [26] Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. *The Stata Journal* 2009; **9**: 265–290. DOI:10.1177/1536867X0900900206.
- [27] Crowther MJ. merlin - a unified modelling framework for data analysis and methods development in Stata. *The Stata Journal* 2020; URL <https://arxiv.org/abs/1806.01615>. To appear.
- [28] Leon DA, Shkolnikov VM, Smeeth L, Magnus P, Pechholdová M, Jarvis CI. COVID-19: A need for real-time monitoring of weekly excess deaths. *The Lancet* 2020; **395**: e81. DOI:10.1016/S0140-6736(20)30933-8.
- [29] Stafford N. Covid-19: Why Germany’s case fatality rate seems so low. *British Medical Journal* 2020; **369**: m1395. DOI:10.1136/bmj.m1395.
- [30] Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according

to underlying conditions and age: A population-based cohort study. *The Lancet* 2020; DOI:10.1016/S0140-6736(20)30854-0.

- [31] Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection. *Annals of Internal Medicine* 2020; DOI:10.7326/M20-3012.
- [32] Smith GD, Spiegelhalter D. Shielding from covid-19 should be stratified by risk. *British Medical Journal* 2020; **369**. DOI:10.1136/bmj.m2063.

List of Figures

1	Swiss covid-19 cohort. Number of deaths from all causes reported between 2020-02-24 and 2020-05-14 in covid-19 patients (35 and 95 years old, not admitted to a hospital prior to testing, excluding post mortem tests).	14
2	Swiss 2018 population and covid-19 cohorts. Comparison of age densities between the Swiss 2018 population and covid-19 cohorts, separately for females and males.	15
3	Swiss 2018 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2018 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2018 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.	16




Figure 1: Swiss covid-19 cohort. Number of deaths from all causes reported between 2020-02-24 and 2020-05-14 in covid-19 patients (35 and 95 years old, not admitted to a hospital prior to testing, excluding post mortem tests).




Figure 2: Swiss 2018 population and covid-19 cohorts. Comparison of age densities between the Swiss 2018 population and covid-19 cohorts, separately for females and males.




Figure 3: Swiss 2018 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2018 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2018 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.

List of Tables

1	2018 study population. Swiss 2018 population cohort (as of January 1st, 2018) and Swiss covid-19 cohort (SARS-CoV-2 positive cases in a total of 334'271 tests performed in Switzerland between 2020-02-24 and 2020-05-14). The table contains the number of persons meeting the inclusion criteria. "Study population" refers to the number of observations in the two cohorts analysed. *The total number of tests includes multiple counts of persons tested more than once.	18
2	Study populations. Number of observations (N) and age (mean and standard deviation) for females and males 35 to 95 years old and alive on February 23 of the respective year. The first row corresponds to the Swiss covid-19 cohort of 2020. .	19
3	Swiss 2018 population and covid-19 cohorts. Log-hazard ratios (log-HR) and hazard ratios (HR) expressing the risk of being male ("Male") and each year of age ("Age – 65") compared to the baseline hazard in 65 year old females. Main effects were fitted to both cohorts, interaction effects to the Swiss covid-19 cohort only. The interaction effects describe the additional risk on the log-HR or HR scale attributable to the infection. Estimates are given with standard errors (SEs) for log-HRs and 95% confidence intervals (CI) for HRs, the latter and P -values were adjusted for multiplicity.	20
4	Swiss 2018 population and covid-19 cohorts. Absolute and relative mortalities. Estimated number of deaths per 100 000 females or males with corresponding age. Population mortality in the Swiss 2018 cohort (Absolute 2018), mortality in the Swiss covid-19 cohort (Absolute SARS-CoV-2), and the relative SARS-CoV-2 mortality (RM, the ratio of the second to the first column). Confidence intervals were obtained from 95% confidence bands given in Figure 3.	21

Table 1: 2018 study population. Swiss 2018 population cohort (as of January 1st, 2018) and Swiss covid-19 cohort (SARS-CoV-2 positive cases in a total of 334'271 tests performed in Switzerland between 2020-02-24 and 2020-05-14). The table contains the number of persons meeting the inclusion criteria. "Study population" refers to the number of observations in the two cohorts analysed. *The total number of tests includes multiple counts of persons tested more than once.

Criterion	Cohort	
	Swiss 2018	Swiss covid-19
Total	8 544 527	*334 271
Alive Feb 23	8 447 130	
SARS-CoV-2 positive after Feb 23		30 460
Sex known		30 437
35 – 95 years old	5 160 595	23 288
Not in hospital		20 769
Study population	5 160 595	20 769
Deaths	5 578	894

Table 2: Study populations. Number of observations (N) and age (mean and standard deviation) for females and males 35 to 95 years old and alive on February 23 of the respective year. The first row corresponds to the Swiss covid-19 cohort of 2020.

Cohort	Sex:		Female		Male	
	N	Age	N	Age		
COVID-19	11 275 (54.29%)	58.70 (16.32)	9 494 (45.71%)	58.63 (14.59)		
2018	2 651 267 (51.38%)	57.88 (14.88)	2 509 328 (48.62%)	56.22 (13.87)		
2017	2 626 177 (51.41%)	57.78 (14.86)	2 482 559 (48.59%)	56.07 (13.81)		
2016	2 599 315 (51.43%)	57.70 (14.85)	2 454 921 (48.57%)	55.94 (13.75)		
2015	2 569 732 (51.47%)	57.61 (14.83)	2 423 124 (48.53%)	55.80 (13.70)		
2014	2 539 821 (51.53%)	57.53 (14.83)	2 389 282 (48.47%)	55.68 (13.66)		

Table 3: Swiss 2018 population and covid-19 cohorts. Log-hazard ratios (log-HR) and hazard ratios (HR) expressing the risk of being male (“Male”) and each year of age (“Age – 65”) compared to the baseline hazard in 65 year old females. Main effects were fitted to both cohorts, interaction effects to the Swiss covid-19 cohort only. The interaction effects describe the additional risk on the log-HR or HR scale attributable to the infection. Estimates are given with standard errors (SEs) for log-HRs and 95% confidence intervals (CI) for HRs, the latter and *P*-values were adjusted for multiplicity.

Effect	log-HR	SE×10	<i>P</i>-value	HR	95% CI
Female	0			1	
Male	0.40	0.27	< 0.001	1.50	1.40–1.60
Age 65	0			1	
Age – 65	0.09	0.01	< 0.001	1.09	1.09–1.09
covid-19 × Female	0			1	
covid-19 × Male	0.18	0.73	0.05	1.20	1.00–1.44
covid-19 × Age 65	0			1	
covid-19 × Age – 65	0.04	0.03	< 0.001	1.04	1.03–1.05

Table 4: Swiss 2018 population and covid-19 cohorts. Absolute and relative mortalities. Estimated number of deaths per 100 000 females or males with corresponding age. Population mortality in the Swiss 2018 cohort (Absolute 2018), mortality in the Swiss covid-19 cohort (Absolute SARS-CoV-2), and the relative SARS-CoV-2 mortality (RM, the ratio of the second to the first column). Confidence intervals were obtained from 95% confidence bands given in Figure 3.

Sex	Age	Mortality			
		Absolute 2018	Absolute SARS-CoV-2	Relative (RM)	
Female	35	5 (4–6)	43 (27–66)	9 (6–15)	
	40	7 (6–8)	77 (51–114)	11 (7–17)	
	45	11 (9–12)	138 (96–196)	13 (8–19)	
	50	17 (15–19)	247 (179–339)	15 (10–21)	
	55	25 (23–28)	443 (334–587)	17 (13–24)	
	60	39 (36–42)	794 (619–1 018)	20 (15–27)	
	65	59 (55–64)	1 421 (1 142–1 768)	24 (19–30)	
	70	91 (86–97)	2 538 (2 094–3 073)	28 (22–34)	
	75	140 (132–148)	4 511 (3 802–5 348)	32 (27–39)	
	80	214 (202–226)	7 955 (6 798–9 300)	37 (31–44)	
	85	327 (308–347)	13 832 (11 888–16 062)	42 (36–50)	
	90	500 (468–535)	23 459 (20 165–27 192)	47 (40–55)	
	95	766 (710–825)	38 127 (32 783–44 022)	50 (42–58)	
	Male	35	7 (6–8)	82 (55–122)	12 (7–18)
		40	11 (9–12)	147 (102–210)	14 (9–20)
45		16 (14–18)	264 (191–363)	16 (11–23)	
50		25 (22–27)	473 (356–628)	19 (14–26)	
55		38 (35–41)	848 (661–1 087)	22 (17–29)	
60		58 (54–62)	1 517 (1 221–1 883)	26 (21–33)	
65		89 (84–95)	2 708 (2 244–3 265)	30 (25–37)	
70		136 (129–144)	4 810 (4 083–5 662)	35 (29–42)	
75		209 (198–221)	8 472 (7 313–9 805)	41 (35–47)	
80		320 (302–338)	14 699 (12 794–16 858)	46 (40–53)	
85		489 (460–520)	24 836 (21 654–28 395)	51 (44–59)	
90		748 (698–802)	40 113 (35 000–45 677)	54 (46–62)	
95		1 144 (1 058–1 237)	60 177 (52 995–67 468)	53 (46–59)	

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther

A. Online Supplement

A.1. Statistical analysis

For the population cohort of a given year, all inhabitants of Switzerland alive and aged between 35 and 95 years old at February 23 enter the risk set. Inhabitants surviving 80 days were censored after 80 days, and those who died within 80 days after February 23 were recorded as an event. To be able to evaluate mortality rates and ratios on the same timescale, allowing for seasonal effects, for the covid-19 cohort, a delayed entry approach was taken, as patients do not become at risk of death until their date of positive test. All deaths in this cohort were treated as events. Individuals without a death record were administratively right-censored 80 days after February 23.

We therefore modelled time-to-death from any cause within 80 days after February 23 (the first positive SARS-CoV-2 test was recorded February 24, 2020; the database was closed on 2020-05-14). The mortality rate in the Swiss covid-19 cohort was compared to the mortality rate in the Swiss 2018 population cohort during the same time of year. Hazard ratios were estimated by a Cox proportional hazards model expressing the distribution of time-to-death after February 23 in days $t > 0$. We fitted a Cox model allowing separate baseline hazard functions, assuming

$$\begin{aligned} h(t \mid \text{male, age, covid-19}) = & \\ & h_{2018}(t)^{1-\delta} \times h_{\text{covid-19}}(t)^\delta \\ & \times \exp(\beta_1 \text{male} + \beta_2(\text{age} - 65) + \beta_3(\delta \times \text{male}) + \beta_4(\delta \times (\text{age} - 65))) \end{aligned}$$

where $h_{2018}(t)$ is the baseline mortality rate at time t , for a 65 year old female in the Swiss 2018 population cohort, $h_{\text{covid-19}}(t)$ describes the mortality rate in the Swiss covid-19 cohort for (on the same calendar timescale to account for seasonal effects), and δ takes the value of 1 if the individual is in the covid-19 cohort, and 0 if the individual is in the 2018 cohort. The linear predictor is parameterised in such a way that we can quantify the effects of age and being male in the general population by the hazard ratios $\exp(\beta_1)$ and $\exp(\beta_2)$, respectively, and the *additional* increase/decrease in the hazard attributable to age and being male in the covid-19 cohort, described by the $\exp(\beta_3)$ and $\exp(\beta_4)$, respectively. The proportional hazards assumption was assessed by comparing the in-sample log-likelihood of the model described above to the in-sample log-likelihood of a Cox model with time-varying sex- and age-effects. The simpler model assuming proportional hazards maximised the log-likelihood at -5386.64 and the model not assuming proportional hazards at -5379.64 , suggesting that mortalities were appropriately modelled under proportional hazards.

For the estimation and comparison of absolute risk, i.e. the probability of dying by time t , we model the mortality rate in the covid-19 cohort on the time since diagnosis timescale. Therefore, the model for the 2018 cohort remains the same, and we are interested in the probability of death 60 days after February 23, 2018. In the covid-19 cohort, we are interested in the probability of death 60 days after diagnosis. Two separate Cox models were fitted to the cohorts with the appropriate timescales. Relative mortality (RM), at time t , is then defined as,

$$\text{RM}(t \mid \text{sex, age}) = \frac{\text{P}(t \mid \text{sex, age, 1})}{\text{P}(t \mid \text{sex, age, 0})}$$

Relative covid-19 Mortality


Supplementary Table 1: Swiss 2018 population and covid-19 cohorts. Log-hazard ratios (log-HR) and hazard ratios (HR) expressing the risk of being male (“Male”) and each year of age (“Age–65”) compared to the baseline hazard in 65 year old females, based on a Cox proportional hazards model with sex \times age interaction. Estimates are given with standard errors (SEs) for log-HRs and 95% confidence intervals (CI) for HRs, the latter and P -values were adjusted for multiplicity.

Effect	log-HR	SE \times 10	P -value	HR	95% CI
Female	0			1	
Male	0.36	0.34	< 0.001	1.44	1.32–1.57
Age 65	0			1	
Age – 65	0.08	0.02	< 0.001	1.09	1.08–1.09
Male \times Age – 65	0.00	0.02	0.2	1.00	1.00–1.01
covid-19 \times Female	0			1	
covid-19 \times Male	0.09	1.40	1.0	1.09	0.76–1.56
covid-19 \times Age 65	0			1	
covid-19 \times Age – 65	0.04	0.05	< 0.001	1.04	1.03–1.05
covid-19 \times Male \times Age – 65	0.00	0.07	1.0	1.00	0.99–1.02

which is the ratio of the probability $P(t \mid \text{sex, age, 1})$ to die within t days after a positive SARS-CoV-2 test and the probability $P(t \mid \text{sex, age, 0})$ to die within t days after February 23, 2018 without an infection for female or male persons of a specific age. We used a time horizon of $t = 60$ days. A relative mortality $\text{RM}(60 \mid \text{female, 65}) = X$ means that the probability to die within 60 after an SARS-CoV-2 infection is X times larger than the population probability to die within 60 days after February 23, 2018, for 65 year old females. Proportional hazards models for absolute risk were estimated with log-cumulative baseline hazard functions parameterised in terms of a Bernstein polynomial²², that is, using a parametric equivalent of the semiparametric Cox model.

In all models, the assumption of a linear age effect was assessed by comparing the linear Cox proportional hazards model to a Cox proportional model featuring a nonlinear additive effect of age on the log-hazard (Figure 1). For the 2018 population cohort, differences were marginal and justified the use of a linear age term. For the Swiss covid-19 cohort, the nonlinear model suggested a stronger age effect up to 80 years, which then levelled-off for older people. The discrepancy between the nonlinear and the linear Cox model in terms of the estimated probability of death at day 80 can be inferred from Figure 2. For the 2018 population cohort, the probability of death from both models were very similar, with some variation for people older than 90 years, which can be explained by the sharp increase of the corresponding log-hazard ratio (Figure 1). In the age range between 60 and 90 years, the two models were relatively similar ($\pm 25\%$), however, the nonlinear model suggested the probability of death was 50% reduced compared to probability of death from the linear model. This means that the relative mortalities assuming a linear effect of age on the log-hazard scale (Figure 3 and Table 4) could be up to two times smaller for people younger than 60 and up to two times larger for persons around 80 years old in a more complex model allowing a nonlinear effect of age. We also considered an interaction between sex and age, but found no difference (Table 1).

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther



Supplementary Figure 1: Swiss 2018 population and covid-19 cohorts. Evaluation of linearity assumption on age. A Cox proportional hazards model was refitted allowing a nonlinear additive impact of age on the log-hazard function. The age effects of the linear Cox model, for females in the two study cohorts, are compared on the log-hazard ratio scale.

A.2. Computational details

Computations were performed in R version 4.0.1²⁰. Cox proportional hazards models were fitted semiparametrically to estimate log-hazard ratios using the **survival**²¹ package. Absolute mortalities were obtained from Cox models, parametrically parameterised with flexible log-cumulative baseline hazard function, using package **mlt**^{23,33}. Confidence bands were computed using the **multcomp** package.


A.3. Sensitivity analysis

The primary analyses were conducted in R; however, to ensure validity and robustness, all analyses were replicated independently in **Stata** by using a flexible parametric survival model²⁵ using the **stpm2**²⁶ and **merlin**²⁷ commands, which can be considered a parametric equivalent to the Cox model but use restricted cubic splines to directly model the baseline (log cumulative) hazard function. We found complete agreement across software platforms, and modelling approaches.

Furthermore, the sensitivity of the main findings reported was assessed by conducting the same analyses, but using the population data from 2014 to 2017, independently, as the comparative populations, instead of the 2018 cohort.


Age distributions and baseline cumulative hazards for these study populations are given in Figures 3, 5, 7, and 9. Absolute and relative mortalities can be obtained from Figures 4, 6, 8, and 10. Hazard ratios for all study populations are presented in Table 2. The deviations from the main results were marginal.

Relative covid-19 Mortality



Supplementary Figure 2: Swiss 2018 population and covid-19 cohorts. Comparison of linear and nonlinear Cox models. The ratio of absolute mortalities (nonlinear model vs. linear model) as a function of age, separately for females and males and the two study cohorts is displayed.

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther




Supplementary Figure 3: Swiss 2017 population and covid-19 cohorts. Comparison of age densities between the Swiss 2017 population and covid-19 cohorts, separately for females and males.

Supplementary Table 2: 2014-2018 study populations. Hazard ratios expressing the risk of being male (“Male”) and each year of age (“Age – 65”) compared to 65 year old females. Each row corresponds to the study population consisting of the Swiss covid-19 cohort and the population cohort of the respective year.


	Male	Age-65	covid-19 × Male	covid-19 × Age-65
2018	1.50 (1.40–1.60)	1.09 (1.09–1.09)	1.20 (1.00–1.44)	1.04 (1.03–1.05)
2017	1.57 (1.47–1.68)	1.09 (1.09–1.09)	1.15 (0.96–1.38)	1.04 (1.03–1.05)
2016	1.52 (1.42–1.62)	1.09 (1.09–1.09)	1.19 (0.99–1.42)	1.04 (1.03–1.05)
2015	1.56 (1.46–1.67)	1.09 (1.09–1.09)	1.15 (0.96–1.38)	1.04 (1.03–1.05)
2014	1.58 (1.47–1.69)	1.09 (1.09–1.09)	1.14 (0.95–1.37)	1.04 (1.03–1.05)

Relative covid-19 Mortality




Supplementary Figure 4: Swiss 2017 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2017 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2017 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther




Supplementary Figure 5: Swiss 2016 population and covid-19 cohorts. Comparison of age densities between the Swiss 2016 population and covid-19 cohorts, separately for females and males.

Relative covid-19 Mortality




Supplementary Figure 6: Swiss 2016 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2016 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2016 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther




Supplementary Figure 7: Swiss 2015 population and covid-19 cohorts. Comparison of age densities between the Swiss 2015 population and covid-19 cohorts, separately for females and males.

Relative covid-19 Mortality




Supplementary Figure 8: Swiss 2015 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2015 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2015 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.

Hothorn, Bopp, Günthard, Keiser, Roelens, Weibull & Crowther



Supplementary Figure 9: Swiss 2014 population and covid-19 cohorts. Comparison of age densities between the Swiss 2014 population and covid-19 cohorts, separately for females and males.

Relative covid-19 Mortality



Supplementary Figure 10: Swiss 2014 population and covid-19 cohorts. Comparison of absolute mortality (the probability of dying from any cause after 60 days, plotted on logarithmic scale) between the Swiss 2014 population and covid-19 cohorts, separately for females and males of different ages (top). Comparison of relative mortality (RM, the ratio of absolute mortalities in the covid-19 versus the 2014 cohort) between the two cohorts, for females and male of different ages (bottom). All estimates are plotted with 95% confidence bands.